{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:48:15Z","timestamp":1787320095707,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.survophthal.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T07:53:45Z","timestamp":1772870025000},"page":"1459-1467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of conbercept, ranibizumab and laser in retinopathy of prematurity: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"given":"Xuemei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Linghu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9902","key":"10.1016\/j.survophthal.2026.03.002_bib1","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"issue":"9832","key":"10.1016\/j.survophthal.2026.03.002_bib2","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(12)60820-4","article-title":"National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications","volume":"379","author":"Blencowe","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.002_bib3","first-page":"365","article-title":"Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone","volume":"101","author":"Mueller","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2026.03.002_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1037\/ccp0000214","article-title":"Outcomes of psychological therapies for prisoners with mental health problems: a systematic review and meta-analysis","volume":"85","author":"Yoon","year":"2017","journal-title":"J Consult Clin Psychol"},{"issue":"10208","key":"10.1016\/j.survophthal.2026.03.002_bib5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.002_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ophtha.2024.01.006","article-title":"Conbercept versus laser for the treatment of infants with zone II retinopathy of prematurity","volume":"131","author":"Cheng","year":"2024","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.002_bib7","first-page":"292","article-title":"Clinical efficacy of intravitreal conbercept injection and photocoagulation for the treatment of diffuse diabetic macular edema","volume":"43","author":"Xie","year":"2021","journal-title":"Chin J Ocul Traum Occupat Eye Dis"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12886-023-02886-5","article-title":"Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity","volume":"23","author":"Cao","year":"2023","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2026.03.002_bib9","first-page":"45","article-title":"Time course of regression and recovery in retinopathy of prematurity after ranibizumab or laser therapy","volume":"44","author":"Cao","year":"2023","journal-title":"J Med Forum"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.002_bib10","first-page":"144","article-title":"Intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity","volume":"33","author":"Cheng","year":"2017","journal-title":"Chin J Ocul Fundus Dis"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.002_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28987-6","article-title":"A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity","volume":"8","author":"Cheng","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.survophthal.2026.03.002_bib13","doi-asserted-by":"crossref","first-page":"e1004","DOI":"10.1111\/aos.14460","article-title":"Comparison of the effectiveness of conbercept and ranibizumb treatment for retinopathy of prematurity","volume":"98","author":"Cheng","year":"2020","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib14","first-page":"32","article-title":"Observation of the curative effect of intravitreal injection of Conbercept in the treatment of retinopathy of prematurity","volume":"30","author":"Lin","year":"2022","journal-title":"Chin J Strabismus Pediatr Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2026.03.002_bib15","first-page":"858","article-title":"Comparison of the treatment outcomes for retinopathy of prematurity with intravitreal injection of conbercept or ranibizumab","volume":"23","author":"Wang","year":"2021","journal-title":"Chin J Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.002_bib16","first-page":"338","article-title":"Individual dose of intravitreal conbercept for efficacy in retinopathy of prematurity","volume":"37","author":"Jiang","year":"2021","journal-title":"Chin J Ocul Fundus Dis"},{"issue":"8","key":"10.1016\/j.survophthal.2026.03.002_bib17","first-page":"595","article-title":"Comparison of the effect of intravitreal injection of conbercept with different doses in the treatment of retinopathy of prematurity","volume":"36","author":"Zhang","year":"2020","journal-title":"Chin J Ocul Fundus Dis"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.002_bib18","first-page":"143","article-title":"Effects of intravitreal injection of compaq spray for the treatment of retinopathy of prematurity","volume":"22","author":"Shen","year":"2020","journal-title":"Chin J Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.002_bib19","first-page":"109","article-title":"The efficacy among different dose of intravitreal conbercept injection for the treatment of retinopathy of prematurity","volume":"22","author":"Sun","year":"2020","journal-title":"Chin J Ocul Trauma Occup Eye Dis"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.002_bib20","first-page":"171","article-title":"Efficacy and related factors of intravitreal injection with conbercept for retinopathy of premature","volume":"35","author":"Zhang","year":"2019","journal-title":"Chin J Ocul Fundus Dis"},{"issue":"7","key":"10.1016\/j.survophthal.2026.03.002_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bjophthalmol-2020-318026","article-title":"Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial","volume":"106","author":"Wu","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.002_bib22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/bjophthalmol-2017-311662","article-title":"Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity","volume":"103","author":"Bai","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2026.03.002_bib23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.002_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042384","article-title":"Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis","volume":"11","author":"Kong","year":"2021","journal-title":"BMJ Open"},{"issue":"14","key":"10.1016\/j.survophthal.2026.03.002_bib25","first-page":"2388","article-title":"Efficacy and Safety of Different Doses of Conbercept Intravitreal Injection in the Treatment of Retinopathy of Prema-turity [J]","volume":"34","author":"Chu","year":"2021","journal-title":"J Med Theory Pr"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.002_bib26","first-page":"172","article-title":"Observation on the short-term efficacy of different doses of conbercept in the treatment of retinopathy of prematurity","volume":"44","author":"Chu","year":"2022","journal-title":"Chin J Ocul Trauma Occup Eye Dis"},{"issue":"9","key":"10.1016\/j.survophthal.2026.03.002_bib27","first-page":"736","article-title":"Efficacy and safety of conbercept and aflibercept in treatment of patients with retinopathy of prematurity","volume":"42","author":"Feng","year":"2022","journal-title":"Recent Adv Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.03.002_bib28","series-title":"Anti-vascular Endothelial Growth Factor Drugs for Retinopathy of Prematurity","author":"Fu","year":"2020"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib29","first-page":"62","article-title":"Intraocular pressure changes in early stage of aggressive posterior retinopa-thy of prematurity treated by vitreous injection of conbercept","volume":"41","author":"Fu","year":"2021","journal-title":"Recent Adv Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.002_bib30","first-page":"92","article-title":"Conbercept combined with laser therapy for aggressive retinopathy of prematurity","volume":"32","author":"Guo","year":"2018","journal-title":"J Otolaryngol Ophthalmol Shandong Univ"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib31","first-page":"80","article-title":"Application value of low-dose conbercept in treatment of retinopathy of prematurity","volume":"30","author":"Jiang","year":"2022","journal-title":"China Med Eng"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.002_bib32","first-page":"866","article-title":"Comparison of the effectiveness of conbercept versus ranibizumab in the treatment of type 1 retinopathy of prematurity","volume":"21","author":"Li","year":"2021","journal-title":"Int J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2026.03.002_bib33","first-page":"1425","article-title":"Observation of the therapeutic effect of Kangbaicipu in treatment of threshold stage pre- threshold lesion type I retinopathy of prmaturity","volume":"51","author":"Shen","year":"2019","journal-title":"Inn Mong Med J"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.002_bib34","first-page":"380","article-title":"Efficacy of intravitreal injection of conbercept for the treatment of retinopathy of prematurity","volume":"31","author":"Zhao","year":"2021","journal-title":"Chin J Hemorh"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib35","first-page":"52","article-title":"Efficacy of six months on intravitreal injection of conbercept for retinopathy of prematurity","volume":"28","author":"Zhou","year":"2019","journal-title":"Ophthalmol China"},{"key":"10.1016\/j.survophthal.2026.03.002_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.911095","article-title":"Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1627 eyes in China","volume":"9","author":"Linghu","year":"2022","journal-title":"Front Med"},{"issue":"19","key":"10.1016\/j.survophthal.2026.03.002_bib37","first-page":"135","article-title":"Clinical efficacy analysis of intravitreal ranibizumab for retinopathy of prematurity","volume":"24","author":"Sun","year":"2018","journal-title":"Contemp Med"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib38","first-page":"14","article-title":"The efficacy of laser photocoagulation and intravitreal ranibizumab treatment of retinopathy of premature","volume":"31","author":"Sun","year":"2015","journal-title":"Chin J Ocul Fundus Dis"},{"issue":"10","key":"10.1016\/j.survophthal.2026.03.002_bib39","first-page":"1040","article-title":"One-year outcomes of intravitreal ranibizumab and laser photocoagulation for zone \u2161 retinopathy of prematurity","volume":"43","author":"Wang","year":"2022","journal-title":"Acad J Chin PLA Med Sch"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib40","first-page":"131","article-title":"Effects of intravitreal ranibizumab on clinical outcomes and retinal functional development in infants with retinopathy of prematurity","volume":"20","author":"Xin","year":"2020","journal-title":"Prog Mod Biomed"},{"issue":"10","key":"10.1016\/j.survophthal.2026.03.002_bib41","first-page":"776","article-title":"Comparison of the efficacy of laser photocoagulation and anti-VEGF in the treatment of type 1 prethreshold retinopathy of prematurity","volume":"36","author":"Xiong","year":"2021","journal-title":"Eye Sci"},{"issue":"22","key":"10.1016\/j.survophthal.2026.03.002_bib42","first-page":"135","article-title":"Intravitreal injection of ralizumab for the treatment of retinopathy of prematurity","volume":"31","author":"Yin","year":"2021","journal-title":"Shenzhen J Integr Tradit Chin West Med"},{"issue":"29","key":"10.1016\/j.survophthal.2026.03.002_bib43","first-page":"54","article-title":"Efficacy and safety of intravitreal injection of ranibizumab in the treatment of retinopathy of prematurity","volume":"7","author":"Zhang","year":"2022","journal-title":"Clin Res Pract"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.002_bib44","first-page":"154","article-title":"Clinical efficacy analysis of laser photocoagulation versus intravitreal ranibizumab for retinopathy of prematurity","volume":"15","author":"Zhang","year":"2017","journal-title":"Guide China Med"},{"issue":"Suppl_1","key":"10.1016\/j.survophthal.2026.03.002_bib45","first-page":"SA76","article-title":"Treatment of retinopathy of prematurity: comparative analysis of intravitreal ranibizumab vs laser treatment 7 years' experience at level 3 Nicu, Saudi Arabia","volume":"106","author":"Elabbasy","year":"2021","journal-title":"Arch Dis Child"},{"issue":"7","key":"10.1016\/j.survophthal.2026.03.002_bib46","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","article-title":"Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW trial","volume":"6","author":"Fleck","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.002_bib47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","journal-title":"Curr Eye Res"},{"issue":"7","key":"10.1016\/j.survophthal.2026.03.002_bib48","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"issue":"9","key":"10.1016\/j.survophthal.2026.03.002_bib49","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2018-312272","article-title":"Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety","volume":"103","author":"Kang","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12886-018-0973-1","article-title":"The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units","volume":"18","author":"Leng","year":"2018","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.002_bib51","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone ii treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.survophthal.2026.03.002_bib52","first-page":"786","article-title":"Comparison of the efficacy of different doses of conbercept in the treatment of retinopathy of prematurity","volume":"37","author":"Lin","year":"2022","journal-title":"Eye Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001166","article-title":"Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity","volume":"8","author":"Jang","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.03.002_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jclinepi.2016.04.015","article-title":"Methods for detecting, quantifying, and adjusting for dissemination bias in meta-analysis are described","volume":"80","author":"Mueller","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.002_bib55","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1111\/aos.15753","article-title":"Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry \u2013 an exemplary comparison between 2011 and 2021","volume":"102","author":"Winter","year":"2024","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.002_bib56","first-page":"94","article-title":"Analysis of treatment and screening for retinopathy of prematurity in newborns with different gestational age","volume":"45","author":"Liu","year":"2023","journal-title":"Chin J Ocul Trauma Occup Eye Dis"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.002_bib57","first-page":"170","article-title":"Clinical characteristics and effect of anti-vascular endothelial growth factor therapy in retinopathy of prematurity in Sichuan province","volume":"39","author":"Liu","year":"2023","journal-title":"Chin J Ocul Fundus Dis"},{"issue":"19","key":"10.1016\/j.survophthal.2026.03.002_bib58","first-page":"3342","article-title":"Comparative clinical efficacy of conbercept versus ranibizumab for retinopathy of prematurity","volume":"36","author":"Li","year":"2023","journal-title":"J Med Theory Pract"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.002_bib59","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.002_bib60","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: a meta-analysis of 3701 eyes","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.002_bib61","first-page":"285","article-title":"Anti-VEGF therapy and laser therapy for type 1 retinopathy of prematurity: a meta-analysis","volume":"21","author":"Xiong","year":"2021","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.03.002_bib62","article-title":"Effect of ranibizumab on retinopathy of prematurity: a meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharm"},{"issue":"9","key":"10.1016\/j.survophthal.2026.03.002_bib63","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/bjophthalmol-2021-319131","article-title":"Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity","volume":"106","author":"Cheng","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2026.03.002_bib64","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41433-021-01922-2","article-title":"The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review","volume":"36","author":"Chow","year":"2022","journal-title":"Eye"},{"issue":"11","key":"10.1016\/j.survophthal.2026.03.002_bib65","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1097\/IAE.0000000000004222","article-title":"Administering intravitreal bevacizumab for retinopathy of prematurity: 8-year cognitive outcomes in a prospective cohort","volume":"44","author":"Wu","year":"2024","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.002_bib66","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:55:30Z","timestamp":1784278530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0039625726000354"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.03.002","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of conbercept, ranibizumab and laser in retinopathy of prematurity: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}